High level of low density lipoprotein cholesterol in blood may turn life-threatening, as it deposits in the blood vessels, narrowing the lumen, and leads to coronary heart diseases.
High level of low density lipoprotein (LDL) cholesterol in blood may turn life-threatening, as it deposits in the blood vessels, narrowing the lumen, and leads to coronary heart diseases. This condition is commonly called atherosclerosis. LDL apheresis is a procedure that involves withdrawing blood from the patient’s body, removing LDL cholesterol and pumping the remaining blood back into the patient’s body. The LDL apheresis procedure is recommended to patients with familial hypercholesterolemia (FH), a common genetic disorder that leads to a high level of LDL cholesterol. This procedure is also performed for patients who are non-responsive to medications for lowering blood LDL cholesterol levels. The heterozygous type of FH has prevalence of 1 in 500 across all the countries, while the homozygous FH is found in 1 in 10 million population.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28493
According to the World Health Organization, in 2008, the prevalence of elevated total cholesterol was 54% in Europe, 48% in North America, and 29% in Southeast Asia. It is estimated that one-third of the heart diseases are caused due to elevated level of cholesterol in the blood. Lifestyle-induced diseases, pollution, and other metabolic diseases are further projected to increase the number of patients with atherosclerosis. Other application areas for LDL apheresis therapy are under study such as renal diseases, hematology diseases, and others. This is projected to drive the demand for LDL apheresis machines and disposables in the near future. Moreover, favorable reimbursement scenario in developed markets such as North America and Europe is driving more patients to opt for LDL apheresis therapy. However, the procedure attracts high capital investment in terms of device and set up. It also attract expensive consumables and skilled healthcare professionals to perform the procedure, which in turn makes the procedure expensive.
Request for Analysis of COVID-19 Impact on LDL Apheresis Therapy Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=28493
The global LDL apheresis therapy market is segmented on the basis of product, technology, and end-user. In terms of product, the global LDL apheresis therapy market can be segmented into devices and disposables, the disposable segment include columns, filters, tubing, etc. In terms of technology, the global LDL apheresis therapy market can be segmented into double filtration plasmapheresis or cascade filtration, immunoadsorption, heparin-induced LDL precipitation (HELP), dextran sulphate lipid adsorption, and hemoperfusion. The hemoperfusion is performed by advanced procedures such as direct adsorption of lipoproteins (DALI) and whole blood perfusion (Liposorber D). Dextran sulfate lipid adsorption and HELP are the most widely employed techniques for LDL apheresis in recent years. However, technically advanced hemoperfusion systems are found to be more promising and are anticipated to dominate the market in near future due to their efficiency and simplicity of use. In terms of end-user, the global LDL apheresis therapy market can be segmented into hospitals, ambulatory surgical centers, and blood banks.
Pre Book LDL Apheresis Therapy Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=28493<ype=S
In terms of geography, the global LDL apheresis therapy market can be segmented into North America, Europe, Asia Pacific, and Rest of the World. North America is estimated to hold a prominent share of the global LDL apheresis therapy market and is anticipated to expand at a high growth rate due to acceptance of technology, well-established healthcare industry, and high healthcare expenditure from the public and private sector. Europe is projected to follow North America in terms of share of the global LDL apheresis therapy market due to increasing prevalence of elevated cholesterol in blood and developments in healthcare infrastructure. Technical advancements in markets such as Japan and increasing healthcare expenditure in emerging markets such as India and China are likely to propel the LDL apheresis therapy market in Asia Pacific in the near future.
Read more information here:
https://www.transparencymarketresearch.com/ldl-apheresis-therapy-market.html
Major players operating in the global LDL apheresis therapy market include Kaneka Pharma Europe N.V, B. Braun Melsungen AG, Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Medical Co., Ltd., Medicap GmbH, Kawasumi Laboratories Inc. Terumo Corporation, and Haemonetics Corporation.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453